Intratect (Human Normal Immunoglobulin)

Human normal immunoglobulin supplies a broad spectrum of IgG antibodies that replace missing or deficient antibodies in patients. The IgG binds to pathogens, neutralizes toxins, and interacts with immune cell receptors to modulate complement activation, suppress auto‑antibody activity, and reduce inflammatory cytokine release, thereby restoring immune balance.

The dosing regimen for Intratect is individualized by the prescribing clinician based on the patient’s weight, IgG trough levels, and specific indication. Typical regimens range from 0.2 to 2 g/kg administered intravenously at intervals determined by the treating physician. Exact dosing should follow the prescriber’s order.

Safety data for Intratect in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Use during pregnancy or while breastfeeding should be considered only if the potential benefit justifies any potential risk to the fetus or infant, and under close medical supervision.

To request Intratect, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Intratect is an EU‑sourced, high‑purity human normal immunoglobulin comparable to other licensed IVIG preparations in terms of IgG content and safety profile. Differences may exist in manufacturing processes, stabilizers, and infusion tolerability, but clinical efficacy for approved indications is generally equivalent across reputable IVIG brands.

Intratect must be stored refrigerated at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. Prior to infusion, the solution should be allowed to reach room temperature and inspected for particulates or discoloration. Proper cold‑chain logistics are essential for maintaining product integrity.

Intratect is given as an intravenous infusion through a suitable vein using an infusion set. The rate of infusion is determined by the prescriber and may be adjusted based on patient tolerance. Infusions are typically performed in a clinical setting where vital signs can be monitored throughout the procedure.

The most serious adverse events linked to Intratect include severe allergic reactions such as anaphylaxis, thromboembolic complications (stroke, myocardial infarction, deep‑vein thrombosis), acute renal failure, aseptic meningitis, and hemolytic anemia. Prompt recognition and management of these reactions are critical.

Intratect is contraindicated in patients with a known severe IgA deficiency who have anti‑IgA antibodies, as they are at high risk for anaphylactic reactions. It should also be avoided in individuals with a history of severe hypersensitivity to immunoglobulin products or those with uncontrolled hyperviscosity disorders.